drugset

drugset / Trial / NCT06441812

A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

NCT06441812 ↗

Phase 2 Recruiting 200 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluation the long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

Timeline

Start: 2024-07-19
Primary completion: 2028-09
Completion: 2028-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-1703	Monoclonal antibody	—	Subcutaneous

Indications